Videos

HERO Study TE: Discussion Videos

Search

Patient Selection for ADT Treatment with the Oral GnRH Antagonist in Clinical Practice - Ashley Ross Details In this conversation Alicia Morgans, MD, MPH, and Ashley Ross, MD discusses his considerations of patient selection when using the oral GnRH antagonist, relugolix. Dr. Ross explains his thought process when considering oral ADT therapy for his patients, and outlines three specific scenarios when he leans into recommending its use for his patients and his approach to patient follow-up once oral tre...
Impact of Concomitant Prostate Cancer Therapy of Relugolix in Men with Advanced Prostate Cancer - Daniel J. George Details Daniel George, MD, and Neal Shore, MD, FACS, co-investigators of the Phase III HERO Trial join Alicia Morgans, MD, MPH recapping the 2021 GU ASCO analysis that Dr. Daniel George presented on the efficacy and safety of relugolix vs leuprolide in men with advanced prostate cancer. This was a subgroup analysis assessing the impact of concomitant prostate cancer therapy on the safety and efficacy of t...
First and Only Oral GnRH Receptor Antagonist Orgovyx for the Treatment of Advanced Prostate Cancer - Charles Ryan & Alicia Morgans Details The United States Food and Drug Administration (FDA) approved Orgovyx (relugolix), the first and only oral GnRH receptor antagonist for the treatment of patients with advanced prostate cancer. Alicia Morgans, MD, MPH, and Charles Ryan, MD discuss Orgovyx and what it means to men being treated for advanced prostate cancer who now have an oral ADT treatment option. The FDA approval of Orgovyx is bas...
Journal Club: Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer - Zachary Klaassen Details Christopher Wallis and Zachary Klaassen host this journal club on "Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer," published by the HERO trial investigators in the New England Journal of Medicine simultaneously with the first presentation of the trial results at the ASCO 2020 annual meeting. Sharing background information on androgen deprivation therapy (ADT), as well...
HERO Phase III Trial: Results Comparing Relugolix, an Oral GnRH Receptor Antagonist Vs. Leuprolide Acetate for Advanced Prostate Cancer - Neal Shore Details Relugolix is the first oral GnRH receptor antagonist, which was previously shown to rapidly suppress testosterone levels. Neal Shore joins Alicia Morgans to discuss the results of the HERO phase 3 trial comparing the safety and efficacy of relugolix with leuprolide acetate in advanced prostate cancer patients. Relugolix is an oral, once a day medication, and the trial had a primary endpoint of non...